Ionis Pharmaceuticals IONS Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's pre-tax income?
- Ionis Pharmaceuticals (IONS) reported pre-tax income of -$92.31M in Q1 2026.
- How has Ionis Pharmaceuticals's pre-tax income changed year-over-year?
- Ionis Pharmaceuticals's pre-tax income increased by 37.1% year-over-year, from -$146.82M to -$92.31M.
- What is the long-term trend for Ionis Pharmaceuticals's pre-tax income?
- Over 3 years (2022 to 2025), Ionis Pharmaceuticals's pre-tax income has grown at a 13.7% compound annual growth rate (CAGR), from -$257.99M to -$379.6M.
- What does pre-tax income mean?
- Total profit before accounting for income taxes.
- How do you interpret pre-tax income?
- A key indicator of overall financial health; consistent growth suggests strong operational and financial performance.
- How does pre-tax income compare across companies?
- Standard metric used to compare profitability across different tax jurisdictions and corporate structures.